{"disease":{"id":"mucosal-melanoma","name":"mucosal melanoma"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02506153","title":"Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1301,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01989572","title":"Sargramostim, Vaccine Therapy, or Sargramostim and Vaccine Therapy in Preventing Disease Recurrence in Patients With Melanoma That Has Been Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":815,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04353050","title":"Atypical MOLes and Melanoma Early Detection Study (MoleMed)","phase":"NA","overall_status":"UNKNOWN","enrollment_count":350,"lead_sponsor_name":"Russian Academy of Medical Sciences","has_results":false},{"nct_id":"NCT03698019","title":"A Study to Compare the Administration of Pembrolizumab After Surgery Versus Administration Both Before and After Surgery for High-Risk Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04462965","title":"Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma Phase II Study","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":294,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT03611868","title":"A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":230,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT07400302","title":"Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":220,"lead_sponsor_name":"The First Hospital of Jilin University","has_results":false},{"nct_id":"NCT03178123","title":"The Study of JS001 Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":220,"lead_sponsor_name":"Shanghai Junshi Bioscience Co., Ltd.","has_results":false},{"nct_id":"NCT04830124","title":"Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":173,"lead_sponsor_name":"Mural Oncology, Inc","has_results":false},{"nct_id":"NCT04462406","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":150,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT05086692","title":"A Beta-only IL-2 ImmunoTherapY Study","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":115,"lead_sponsor_name":"Medicenna Therapeutics, Inc.","has_results":false},{"nct_id":"NCT04511013","title":"A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":112,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT05111574","title":"Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":101,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07155317","title":"Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":99,"lead_sponsor_name":"Emory University","has_results":false},{"nct_id":"NCT03033576","title":"Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":94,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT04653038","title":"A Study to Evaluate the Safety and Efficacy of MGD013 in Patients With Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":92,"lead_sponsor_name":"Zai Lab (Shanghai) Co., Ltd.","has_results":false},{"nct_id":"NCT03025256","title":"Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":75,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT00937937","title":"Dinaciclib in Treating Patients With Stage IV Melanoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":72,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT07215988","title":"Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a \"Filter\" Observational Study","phase":"","overall_status":"RECRUITING","enrollment_count":70,"lead_sponsor_name":"Ohio State University Comprehensive Cancer Center","has_results":false},{"nct_id":"NCT07506447","title":"The Value of [18F]FDG PET/CT Imaging in Prognostic Evaluation of Mucosal Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":68,"lead_sponsor_name":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","has_results":false},{"nct_id":"NCT03319693","title":"Molecular Characterization of Primary Mucosal Melanoma","phase":"","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"CHU de Reims","has_results":false},{"nct_id":"NCT02129075","title":"A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":60,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06424626","title":"A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal Melanoma","phase":"PHASE1","overall_status":"NOT_YET_RECRUITING","enrollment_count":60,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT06319196","title":"Clear Me: Interception Trial to Detect and Clear Molecular Residual Disease in Patients With High-risk Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT02519322","title":"Neoadjuvant and Adjuvant Checkpoint Blockade","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":53,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT02126579","title":"Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Craig L Slingluff, Jr","has_results":true},{"nct_id":"NCT04645680","title":"Diet and Immune Effects Trial: DIET- A Randomized Double Blinded Dietary Intervention Study in Patients With Metastatic Melanoma Receiving Immunotherapy","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":50,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT06041724","title":"Envafolimab Combined With Recombinant Human Endostatin and First-line Chemotherapy Treat of Advanced Mucosal Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":46,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT03986515","title":"Apatinib Plus SHR1210 in Advanced Mucosal Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Henan Cancer Hospital","has_results":false},{"nct_id":"NCT07336979","title":"Paclitaxel Polymersomes + Carboplatin + Adebelimab: Neoadjuvant Phase Ⅱ Single-Arm Study for Resectable Mucosal Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04472806","title":"Maintenance Treatment of Toripalimab(JS001) in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":31,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04180995","title":"Toripalimab in Combination With Axitinib in Patients With Localized Mucosal Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT07236528","title":"Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","has_results":false},{"nct_id":"NCT03138642","title":"Mucosal Melanoma of Head and Neck in Intensity-modulated Radiotherapy Era","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":30,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07353073","title":"A Prospective, Single-Arm, Phase II Clinical Study of Neoadjuvant Therapy With Pucotenlimab, Lenvatinib, and Temozolomide for Resectable Head and Neck Mucosal Melanoma (PLT-NAT-HNMM-II)","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","has_results":false},{"nct_id":"NCT05009446","title":"Single Arm Study of Induction Chemoradiotherapy Combined With Surgery in the Treatment of Locally Advanced SNMM","phase":"EARLY_PHASE1","overall_status":"UNKNOWN","enrollment_count":28,"lead_sponsor_name":"Eye & ENT Hospital of Fudan University","has_results":false},{"nct_id":"NCT04622566","title":"Lenvatinib and Pembrolizumab in Resectable Mucosal Melanoma","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":26,"lead_sponsor_name":"Peking University Cancer Hospital & Institute","has_results":false},{"nct_id":"NCT05098210","title":"Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":25,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":false},{"nct_id":"NCT02858869","title":"Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Emory University","has_results":true},{"nct_id":"NCT02158520","title":"Nab-Paclitaxel and Bevacizumab or Ipilimumab as First-Line Therapy in Treating Patients With Stage IV Melanoma That Cannot Be Removed by Surgery","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"Academic and Community Cancer Research United","has_results":true},{"nct_id":"NCT04551352","title":"A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT05420324","title":"A Study to Assess YH003 in Combination with Pebolizumab and Albumin Paclitaxel Injection in Subjects with Unresectable/metastatic Mucosal Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Eucure (Beijing) Biopharma Co., Ltd","has_results":false},{"nct_id":"NCT04318717","title":"Pembrolizumab and Hypofractionated Radiation Therapy for the Treatment of Mucosal Melanoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":19,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT05628883","title":"Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":17,"lead_sponsor_name":"H. Lee Moffitt Cancer Center and Research Institute","has_results":false},{"nct_id":"NCT02978443","title":"A Biomarker Study in Advanced Mucosal or Acral Lentiginous Melanoma Receiving Nivolumab in Combination With Ipilimumab","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Georgetown University","has_results":true},{"nct_id":"NCT05436990","title":"Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Acral and Mucosal Melanoma Patients Progressed From Prior Immune Check Point Inhibitor","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":14,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT03865212","title":"Modified Virus VSV-IFNbetaTYRP1 in Treating Patients With Stage III-IV Melanoma","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":12,"lead_sponsor_name":"Mayo Clinic","has_results":false},{"nct_id":"NCT01961115","title":"Epacadostat and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":11,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT02748564","title":"Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":10,"lead_sponsor_name":"Rutgers, The State University of New Jersey","has_results":true},{"nct_id":"NCT05341349","title":"Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1,"lead_sponsor_name":"Emory University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}